Talquetamab
Talquetamab is a bispecific T-cell engager antibody that simultaneously binds to GPRC5D on multiple myeloma cells and CD3 on T cells, redirecting cytotoxic T cells to kill tumor cells. It is approved for relapsed or refractory multiple myeloma after multiple prior lines of therapy, and is under investigation for leukemia. Its target, GPRC5D, is highly expressed on myeloma cells and plasma cells, providing a selective therapeutic window.
Therapeutic Areas
Mechanism of Action
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
Talquetamab is a bispecific T-cell engager antibody that simultaneously binds to GPRC5D on multiple myeloma cells and CD3 on T cells, redirecting cytotoxic T cells to kill tumor cells. It is approved for relapsed or refractory multiple myeloma after multiple prior lines of therapy, and is under investigation for leukemia. Its target, GPRC5D, is highly expressed on myeloma cells and plasma cells, providing a selective therapeutic window.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Talquetamab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594503. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="talquetamab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/talquetamab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/talquetamab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/talquetamab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="talquetamab"></drugfyi-drug>